DNLI (STOCKS)
Denali Therapeutics Inc. Common Stock
$22.040000
+0.380000 (+1.75%)
Prev close: $21.660000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Ryan J. Watts
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,528.12M
- Employees
- 517
- P/E (TTM)
- -7.71
- P/B (TTM)
- 3.71
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
12
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.69 | $-0.74 | +0.0505 | +6.82% |
|
Dec 2025 (Q4)
|
$-0.73 | $-0.76 | +0.0290 | +3.82% |
|
Sep 2025 (Q3)
|
$-0.74 | $-0.77 | +0.0269 | +3.51% |
|
Jun 2025 (Q2)
|
$-0.72 | $-0.73 | +0.0138 | +1.88% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $547.12M |
| Research and Development | $406.40M |
| Other Operating Expenses | $140.72M |
| Operating Income/Loss | -$547.12M |
| Income/Loss From Continuing Operations After Tax | -$508.02M |
| Income/Loss From Continuing Operations Before Tax | -$507.92M |
| Net Income/Loss | -$508.02M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$508.02M |
| Net Income/Loss Available To Common Stockholders, Basic | -$508.02M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.88 |
| Diluted Earnings Per Share | -$2.88 |
| Basic Average Shares | 531,455,231 |
| Diluted Average Shares | 531,455,231 |
| Assets | $1.27B |
| Current Assets | $1.02B |
| Noncurrent Assets | $243.27M |
| Fixed Assets | $51.73M |
| Intangible Assets | $36.00M |
| Other Non-current Assets | $155.54M |
| Liabilities | $339.93M |
| Current Liabilities | $110.16M |
| Accounts Payable | $40.38M |
| Wages | $9.22M |
| Other Current Liabilities | $60.56M |
| Noncurrent Liabilities | $229.77M |
| Equity | $926.10M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $926.10M |
| Liabilities And Equity | $1.27B |
| Net Cash Flow From Operating Activities | -$412.34M |
| Net Cash Flow From Operating Activities, Continuing | -$412.34M |
| Net Cash Flow From Investing Activities | $330.99M |
| Net Cash Flow From Investing Activities, Continuing | $330.99M |
| Net Cash Flow From Financing Activities | $412.02M |
| Net Cash Flow From Financing Activities, Continuing | $412.02M |
| Net Cash Flow | $330.68M |
| Net Cash Flow, Continuing | $330.68M |
| Comprehensive Income/Loss | -$510.74M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$510.74M |
| Other Comprehensive Income/Loss | -$510.74M |
| Other Comprehensive Income/Loss Attributable To Parent | -$2.72M |